About The Study: Among outpatient adults with mild to moderate COVID-19, treatment with fluvoxamine 100 mg twice daily for 13 days, compared with placebo, did not improve time to sustained recovery in this randomized clinical trial of 1,175 participants.
Authors: Susanna Naggie, M.D., M.H.S., of the Duke University School of Medicine in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.23363)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.23363?guestAccessKey=c128b659-6877-4a84-bd2b-8808b25c5e0b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111723
JAMA